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LETTER TO THE EDITOR
High Proportion of Inflammatory Breast Cancer in the
Population-Based Cancer Registry of Gharbiah, Egypt
To the Editor:
Inflammatory breast cancer (IBC), the most lethal
form of breast cancer, constitutes 1–2% of all breast
cancers in the United States (1). Breast cancer com-
prises 352% of women’s cancers in the Gharbiah can-
cer registry (GCR) of Egypt (2). Hospital-based
studies from the National Cancer Institute of Cairo
University (NCI-Cairo) in Egypt suggested that IBC
accounts for 10% of breast cancers (3). However,
these estimates lacked confirmation from population-
based studies. To remedy this deficit, we performed
this study to evaluate the frequency and features of
IBC in GCR.
Our initial review of GCR data between 1999 and
2003 showed that IBC did not exist despite the clini-
cal experience with frequent cases of IBC at the GCR
and the 10% relative frequency of the disease at NCI-
Cairo. A multi-disciplinary group of physicians in
Egypt and the United States, who were experienced in
the diagnosis and management of IBC, collaboratively
developed an 84-item checklist of symptoms, signs,
and clinical characteristic suggestive of IBC to facili-
tate and standardize abstraction of information from
medical records. IBC cases were identified using the
simplified clinical definition of Merajver and Sabel (4)
that used erythema, edema, and peau d’orange as the
three main clinical features of IBC. Subsequently,
cases were grouped as follows: most-likely IBC exhib-
ited all three features, possible IBC cases had any two
of the three symptoms or had peau d’orange only, and
non-IBC cases had edema only, erythema only, or had
none of these three clinical features. IBC status was
based on clinical criteria for IBC diagnosis (erythema,
edema, and peau d’orange). The checklist was applied
to all cases that had at least one of the three defining
features of IBC and missing data was denoted.
The study population had 659 cases, comprising
four with most-likely IBC, 69 with possible IBC, and
586 who were non-IBC. IBC proportion was calcu-
lated according to two different definitions. Under the
most stringent definition, most-likely IBC cases were
considered as IBC, the proportion of IBC was 0.6%.
Under a definition that both most-likely IBC cases and
possible IBC cases were considered as IBC, the IBC
proportion was 11.1%.
There was no difference in age, parity, menopausal
status, concurrent lactation, or family history between
the IBC versus non-IBC groups. Warmth, diffuse
enlargement, and nipple retraction were significantly
higher among the IBC group compared with the
non-IBC group (5.5% versus 0.2% with warmth,
p < 0.01; 8.2% versus 0.7% with diffuse enlargement,
p < 0.01; and 60.9% versus 8.2% with nipple retrac-
tion, p < 0.01, among IBC versus non-IBC groups,
respectively). There were no significant differences
between the two groups in bruising, palpable mass, or
ulceration. The IBC group had 12.5% tumor emboli
compared with 3.6% among the non-IBC group
(p = 0.02). More patients (42.5%) in the IBC group
received neo-adjuvant chemotherapy compared with
15.4% in the non-IBC group (p < 0.01). While 81.9%
of the non-IBC group received surgical resection or
radiotherapy (73.4%), this proportion was significantly
higher than patients receiving resection or radiotherapy
among the IBC group (53.5% and 51.9%, both
p < 0.01). There was no significant difference between
the IBC versus non-IBC groups in tumor grade, angi-
olymphatic invasion, or adjuvant chemotherapy. IBC
cases had higher rate of metastasis (41.7%) compared
with 27.8% for the non-IBC group (p = 0.10). Hor-
mone receptors were higher in the IBC group than the
non-IBC group (36.4% versus 16.7%, p < 0.01 for ER;
58.3% versus 36.2%, p = 0.04 for PR). After adjusting
for warmth and systemic symptoms, nipple retraction
was independently and significantly predictive of IBC
(OR = 18.8, 95% CI: 9.6–37.7).
For the first time, this population-based study con-
firmed what hospital-based and anecdotal reports sug-
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gested, namely that 11% proportion of IBC in Egypt
(3). This IBC proportion in Gharbiah is unequivocally
higher than that in the U.S. and most western coun-
tries where data are available (1,3). We provide a rig-
orous method to ascertain and study IBC in other
populations.
IBC cases in Gharbiah were statistically more likely
to have findings of grave breast cancer such as
warmth, diffuse enlargement, nipple retraction, ER ⁄ PR
negative, tumor emboli, and higher utilization of neo-
adjuvant chemotherapy, neither of which was used to
define the comparison groups. The finding that nipple
retraction is very common in IBC in Egypt warrants
further investigation and comparison with other
regions of Africa and with migrant North African
populations in the United States and Europe. Tumor
emboli were statistically associated with IBC but not
commonly documented and thus not useful for studies
utilizing registries.
As expected, clinical symptoms, including nipple
retraction and warmth, were strong predictors of IBC,
even after adjusting for tumor emboli, ER and PR sta-
tus. Among other clinical features, erythema, edema,
and peau d’orange had significant associations with
IBC because of our criteria for IBC diagnosis. It is
important to caution that reliance on histologic tumor
emboli may lead to drastic underestimation of IBC
incidence in registries, where quality of pathological
evaluation may be highly variable. Although the pro-
portion of patients receiving adjuvant chemotherapy
was similar among IBC and non-IBC groups,
neo-adjuvant chemotherapy, surgical resection or
radiotherapy were significantly different between IBC
versus non-IBC group. The proportion of IBC patients
who received neo-adjuvant chemotherapy was signifi-
cantly higher than that for non-IBC patients. In con-
trast, a higher proportion of non-IBC patients received
surgical resection or radiotherapy, a consequence of
the fact a larger proportion of IBC patients progress
during neo-adjuvant chemotherapy or develop metas-
tasis prior to initiation of the radiotherapy. Higher
rates of neo-adjuvant chemotherapy among IBC
patients were reassuring and an important test of
internal consistency, as patients receiving neo-adjuvant
chemotherapy are clinically most likely IBC cases,
given that neo-adjuvant treatment is the recommended
standard treatment for IBC in the United States and
Egypt.
Regional variations in IBC proportion may occur
due to differences in diagnostic tools, disease defini-
tion criteria, or difference in incidence because of
diverse residential and environmental exposures. The
International Classification of Disease for Oncology
(ICD-O-2, 8530 ⁄ 3 for IBC) focusing on both clinical
and pathological profiles has been employed in recent
epidemiological investigations that examined the
large-scale population-based Surveillance, Epidemiol-
ogy, and End-Results (SEER) which uses the ICD sys-
tem to collect the data (5). Other studies have used
the American Joint Committee on Cancer (AJCC)
staging as a guideline for diagnosis of subtypes of car-
cinomas including IBC (6). Our study focused on a
minimal clinical definition amenable to be utilized in
population-based studies worldwide.
In summary, this study proved that IBC can be
identified from cancer registries in developing coun-
tries. Such identification should rely on reviewing
breast cancer medical records for specific documenta-
tion of peau d’orange, edema, erythema, and tumor
emboli. Depending on treatment trends in the region
studied, neo-adjuvant chemotherapy, surgical resec-
tion, and radiotherapy data can serve as indicators of
the consistency of IBC diagnosis. This study supports
the reported high proportion of IBC in Egypt in previ-
ous hospital-based studies (3). Future efforts to under-
stand the epidemiology of IBC would be facilitated by
explicitly adding IBC status to cancer registration
forms in population and hospital cancer registries,
especially in developing countries where resources for
research are limited but disease patterns that differ
from developed countries may exist. We provide a
method for ascertainment of IBC patients to perform
future studies. The characterization of IBC in areas of
high incidence may eventually provide opportunities
for better understanding of IBC risk factors and for
channeling limited treatment resources more effec-
tively.
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